Overview
Pharmaceutical

FunPep Company Limited

FunPep is a Japanese biopharmaceutical R&D company specializing in functional peptides and antibody-inducing peptides, with technology originating from Osaka University's Graduate School of Medicine. The company develops peptide-based therapeutics across multiple modalities, including SR-0379 (a skin ulcer treatment in clinical development), FPP003 and FPP004X (antibody-inducing peptide vaccines in clinical trials), and cosmetic/functional food ingredients such as AAPeptide used in Albion's skincare products. Its proprietary 'STEP UP' drug discovery platform enables the creation of diverse antibody-inducing peptides as cost-effective alternatives to high-priced antibody drugs, targeting oncology, inflammation, and other therapeutic areas.

Market Cap
¥2.18B
US$13.9M
EV
¥0.25B
US$1.62M
Stock¥43▲+2.38%
US$1 = ¥156.80 (2026-10-23)
LTM EV/EBITDA
NM
LTM EV/EBIT
NM
LTM PER
NM
LTM PBR
1.3
x
Stock vs TOPIX (1Y, base=100)vs TOPIX ▼-77.4%pt
100
Oct 24, 25 – Oct 23, 26StockTOPIX
MC → EV Bridge
2.18BUS$13.9MMarket Cap0.00BUS$0.00M+ Debt1.89BUS$12.1M− Cash0.03BUS$0.19M− Inv. Sec.0.25BUS$1.62MEV
AI Briefing
Generating insights…
Performance & Balance
Revenue 5Y (¥B)
0.13US$0.80M'21/120.00US$0.01M'22/120US$0.00M'23/120.01US$0.04M'24/120US$0.00M'25/12
EBITDA 5Y (¥B)
-0.74-US$4.74M'21/12-1.16-US$7.38M'22/12-0.96-US$6.12M'23/12-0.87-US$5.54M'24/12-1.62-US$10.3M'25/12
Net Income 5Y (¥B)
-0.68-US$4.35M'21/12-1.17-US$7.47M'22/12-0.93-US$5.95M'23/12-0.89-US$5.67M'24/12-1.91-US$12.2M'25/12
Capital Structure
100%
EquityD/E 0.00xDebt
Liquidity vs Debt 5Y (¥B)▲ Net Cash
CashInv. Sec.Debt
3.01US$19.2M'21/122.25US$14.3M'22/121.79US$11.4M'23/122.38US$15.2M'24/121.80US$11.5M'25/12
Shareholders
Top 10 hold 22.9%
1
Shionogi & Co.,Ltd.
5.29%
2
Rakuten Securities, Inc.
3.64%
3
SBI SECURITIES Co., Ltd.
2.37%
4
SBI 4&5 Investment Limited Partnership
2.35%
5
Toshimi MIYOSHI
2.22%
6
ReBeage Inc.
1.58%
7
New Life Science No. 1 Investment Limited Partnership
1.57%
8
Advanced Technology Co., Ltd.
1.38%
9
BNYM SA/NV FOR BNYM FOR BNY GCM CLIENT ACCOUNTS M LSCB RD (Standing Proxy: MUFG Bank, Ltd.)
1.28%
10
Katsumi YOSHIDA
1.18%
Management
8 officers
Toshimi MIYOSHI
Representative Director, President
Apr 1988 Joined Mitsui Omuta Hospital Apr 1991 Joined Morishita Pharmaceutical Co., Ltd. (now Sanofi K.K.) Oct 1998 Joined Nihon Welcome K.K. (now GlaxoSmithKline K.K.) Dec 2002 Joined Sanofi Synthelabo K.K. (now Sanofi K.K.) Jul 2004 Joined MBL Venture Capital Co., Ltd. Jan 2006 Joined Nikko Ant Factory Co., Ltd. (now Ant Capital Partners Co., Ltd.) Jan 2013 Advisor, Sosei Group Corporation (now Nxera Pharma Co., Ltd.) Oct 2013 Corporate Auditor, the Company Mar 2015 Director, the Company Jul 2016 Joined Sosei Corporate Venture Capital Co., Ltd. (now PF Capital Co., Ltd.) as Director Jan 2020 Representative Director, President, the Company (current)
1964-03-23
Hideki TOMIOKA
Director, Head of Research and Development, and CSO
Apr 1997 Joined Ono Pharmaceutical Co., Ltd. Dec 2005 Joined AnGes MG, Inc. (now AnGes, Inc.) Jul 2015 Joined the Company as Head of Research and Development Dec 2015 Director, the Company, Head of Research and Development Mar 2019 Director, Head of Research and Development, and CSO, the Company (current)
1971-08-13
Takatoshi HAYASHI
Director, Head of Administration, and CFO
Apr 1997 Joined Fuji Research Institute Corporation (now Mizuho Research & Technologies, Ltd.) Jun 2001 Joined MedGene BioScience Co., Ltd. (now AnGes, Inc.) Sep 2007 Head of Corporate Planning, MedGene BioScience Co., Ltd. Feb 2010 Joined Canvas Co., Ltd. Jun 2014 Joined Delta-Fly Pharma, Inc., as Senior General Manager, Financial Management May 2015 Joined the Company as Head of Corporate Planning and CFO Dec 2015 Director, the Company, Head of Administration and CFO (current)
1973-02-17
Norikazu SAKAKI
Director
Apr 1969 Joined Shell Sekiyu K.K. (now Idemitsu Kosan Co., Ltd.) Jun 1973 Joined Matsushita Electric Works, Ltd. (now Panasonic Holdings Corporation) Aug 1979 Joined Nihon Ciba-Geigy K.K. Jan 1994 Joined Bayer Yakuhin, Ltd. Mar 1997 Director, Bayer Yakuhin, Ltd. (Plant Manager, Shiga Plant) Jul 2002 Representative Director, President, Bayer Yakuhin, Ltd. Jan 2007 Representative Director, Chairman, Bayer Yakuhin, Ltd. Apr 2010 Director, Chairman, Bayer Yakuhin, Ltd. May 2014 Director, AnGes, Inc. (current) Jan 2015 Representative Partner, Eiki Consulting LLC (current) Mar 2015 Chairman of the Board, the Company Jun 2015 Director (Audit and Supervisory Committee Member), Towa Pharmaceutical Co., Ltd. Apr 2016 Director, Solasia Pharma K.K. (current) Jan 2017 Director, the Company (current) Jun 2018 Director, Gene Techno Science Co., Ltd. (now Kidswell Bio Co., Ltd.) (current) Jun 2024 Director, Towa Pharmaceutical Co., Ltd. (current)
1948-04-17
Makoto HARA
Director
Apr 1974 Joined Sumitomo Chemical Co., Ltd. Aug 1999 Joined Sumitomo Pharmaceuticals Co., Ltd. (now Sumitomo Pharma Co., Ltd.), General Manager, General Planning Office, and General Manager, Pharmaceutical Business Office, Sumitomo Chemical Co., Ltd. Apr 2003 General Manager, Petrochemical Business Office, Sumitomo Chemical Co., Ltd. Jun 2005 General Manager, Accounting Department, Sumitomo Chemical Co., Ltd.; Executive Officer Apr 2008 Managing Executive Officer, Sumitomo Chemical Co., Ltd. Apr 2010 Senior Managing Executive Officer, Sumitomo Chemical Co., Ltd. Sep 2010 Managing Executive Officer, Dainippon Sumitomo Pharma Co., Ltd. (now Sumitomo Pharma Co., Ltd.) Jun 2011 Director, Managing Executive Officer, Dainippon Sumitomo Pharma Co., Ltd. Apr 2012 Director, Senior Managing Executive Officer, Dainippon Sumitomo Pharma Co., Ltd. Jun 2016 Advisor, Dainippon Sumitomo Pharma Co., Ltd. Oct 2016 Special Advisor, the Company Mar 2018 Director, AnGes, Inc. (current) Mar 2024 Director, the Company (current)
1951-03-15
Motsugu HORIGUCHI
Full-time Corporate Auditor
Mar 1968 Joined Matsushita Electric Industrial Co., Ltd. (now Panasonic Holdings Corporation) May 1985 Joined Toho Pharmaceutical Research Laboratory Co., Ltd. Dec 1993 Joined Amgen K.K. May 2005 Director, Executive Officer, General Manager, Administration Division, Synvia Pharmaceuticals, Inc. Jan 2013 Director, Life Care Network Co., Ltd. (now Future Opportunity Resource Co., Ltd.) Mar 2015 Full-time Corporate Auditor, the Company (current)
1945-05-06
Junya MANABE
Corporate Auditor
Oct 1995 Joined Tohmatsu & Co. (now Deloitte Touche Tohmatsu LLC), Tokyo Office May 2000 Joined Fuji Accounting Office (audit firm) Nov 2006 Joined the Legal Training and Research Institute of the Supreme Court of Japan Dec 2007 Joined Nakamura Law Office Apr 2009 Established M's Law and Accounting Office, Minami-Aoyama, Representative Apr 2010 Visiting Professor, Faculty of Business Administration and Education, Ashiya University Mar 2022 Corporate Auditor, the Company (current) Nov 2025 Outside Director (Audit and Supervisory Committee Member), Welldish Inc. (current) Dec 2025 Representative, Nihon Crease Law Firm (current)
1973-03-01
Naofumi HIGUCHI
Corporate Auditor
Oct 1997 Joined Chuo Audit Corporation Aug 2007 Joined Mizuho Securities Co., Ltd. Aug 2009 Joined the Japanese Institute of Certified Public Accountants Apr 2012 Associate Professor, Graduate School of Accounting, Tohoku University Jan 2013 Joined Taiyo ASG LLC (now Taiyo LLC) Jun 2016 Established Higuchi CPA Office, Representative (current) Jun 2016 Corporate Auditor, Nippon Paper Trading Co., Ltd. (current) Apr 2018 Professor, Graduate School of Accounting, Tohoku University (current) Mar 2020 Director, Nihon Aqua Co., Ltd. Jul 2022 Executive Board Member, Japanese Institute of Certified Public Accountants Mar 2023 Director (Audit and Supervisory Committee Member), Nihon Aqua Co., Ltd. (current) Jun 2023 Corporate Auditor, Japan Management Association Consulting Co., Ltd. (current) Mar 2025 Substitute Corporate Auditor, the Company Jun 2025 Corporate Auditor, the Company (current)
1973-03-19
Large Shareholding Reports
Growth Capital Co., Ltd.
2026-06-09
5.87%→4.66%
Growth Capital Co., Ltd.
2026-06-05
18.48%→18.29%
Growth Capital Co., Ltd.
2026-06-05
18.29%→16.53%
Growth Capital Co., Ltd.
2026-06-05
15.26%→13.84%
Correction filing (name/detail fix only) — ratio carried over from the original filing
Growth Capital Co., Ltd.
2026-06-05
20.72%→18.35%
Growth Capital Co., Ltd.
2026-06-05
6.87%→5.87%
Growth Capital Co., Ltd.
2026-06-05
16.53%→15.26%
Correction filing (name/detail fix only) — ratio carried over from the original filing
Growth Capital Co., Ltd.
2026-06-05
21.37%→20.72%
Growth Capital Co., Ltd.
2026-05-29
7.93%→6.87%
Growth Capital Co., Ltd.
2026-05-25
8.99%→7.93%
Growth Capital Co., Ltd.
2026-05-14
10.06%→8.99%
Growth Capital Co., Ltd.
2026-05-08
11.25%→10.06%
Growth Capital Co., Ltd.
2026-04-23
12.47%→11.25%
Growth Capital Co., Ltd.
2026-04-15
13.84%→12.47%
Growth Capital Co., Ltd.
2026-04-08
15.26%→13.84%
Growth Capital Co., Ltd.
2026-04-02
16.53%→15.26%
Growth Capital Co., Ltd.
2026-04-01
18.42%→16.53%
Growth Capital Co., Ltd.
2026-03-25
18.48%→18.42%
Growth Capital Co., Ltd.
2026-03-24
20.40%→18.48%
Growth Capital Co., Ltd.
2026-03-19
21.37%→20.40%
Growth Capital Co., Ltd.
2026-03-16
21.37%
Disclosures
No disclosures
Primary Source Filings
EDINET
2026-08-14
Semi-Annual Securities Report
Period: Jan 2026 – Dec 2026
TDnet
2026-08-14
Q2 Earnings Flash
FY ending Dec 2026
EDINET
2026-06-09
Large Shareholding Report
EDINETAmended
2026-06-05
Change Report
EDINETAmended
2026-06-05
Change Report
EDINETAmended
2026-06-05
Change Report
EDINETAmended
2026-06-05
Change Report
EDINETAmended
2026-06-05
Change Report
EDINETAmended
2026-06-05
Change Report
EDINET
2026-06-05
Large Shareholding Report
EDINET
2026-05-29
Large Shareholding Report
EDINET
2026-05-25
Large Shareholding Report
EDINET
2026-05-14
Large Shareholding Report
TDnet
2026-05-12
Q1 Earnings Flash
FY ending Dec 2026
EDINET
2026-05-08
Large Shareholding Report
EDINET
2026-04-23
Large Shareholding Report
EDINET
2026-04-15
Large Shareholding Report
EDINET
2026-04-08
Large Shareholding Report
EDINET
2026-04-02
Large Shareholding Report
EDINET
2026-04-01
Large Shareholding Report
EDINET
2026-03-25
Large Shareholding Report
EDINET
2026-03-24
Annual Securities Report
Period: Jan 2025 – Dec 2025
EDINET
2026-03-24
Large Shareholding Report
EDINET
2026-03-19
Large Shareholding Report
EDINET
2026-03-16
Large Shareholding Report
EDINET
2026-02-20
Securities Registration Statement
TDnet
2025-11-14
Q3 Earnings Flash
FY ending Dec 2025
EDINET
2025-08-14
Semi-Annual Securities Report
Period: Jan 2025 – Dec 2025
TDnet
2025-05-14
Q1 Earnings Flash
FY ending Dec 2025
EDINET
2025-03-28
Annual Securities Report
Period: Jan 2024 – Dec 2024
Ask AI
I have this company's financials, ownership, and management on hand. Ask me anything from an M&A perspective.
End of Preview

Try the full product

Free demo (no time limit, up to 10 companies). Explore Comps, DCF, LBO, WACC on every screen. Excel export is on the paid plan.

Free Demo (No Time Limit, 10 Companies) →